Spartan Bioscience, a point-of-care DNA testing company, has announced that it has submitted a 510(k) pre-market notification application to the FDA requesting regulatory clearance for its Spartan RX CYP2C19 genetic test.
CYP2C19 is an enzyme that metabolizes commonly-prescribed drugs, including antiarrhythmics, proton pump inhibitors, antidepressants, and antiplatelet drugs. About 30% of Caucasians, 40% of Africans, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(1,2,3,4)
Read more:
Spartan RX
Source: Spartan RX
Art and Science of Laboratory Medicine
Web site: laboratoryeqas.exai.com
Facebook: www.facebook.com/LaboratoryEQAS
Twitter: LaboratoryEQAS
No comments:
Post a Comment